Neurava

Executive Summary

Neurava is a US-based medical device company founded in 2018, developing an AI-powered wearable platform to address the critical unmet need in uncontrolled epilepsy management. The platform uniquely integrates a seizure-sensing device with multi-parameter physiological monitoring to detect not only seizures but also cardiorespiratory biomarkers associated with Sudden Unexpected Death in Epilepsy (SUDEP). By combining real-time monitoring with a connected app and physician portal, Neurava aims to provide patients and caregivers with actionable insights, potentially reducing SUDEP risk and improving quality of life. The company targets a market of approximately one million patients with drug-resistant epilepsy in the US alone, offering a differentiated approach compared to existing seizure detection devices that do not monitor SUDEP-related biomarkers. Neurava is positioned at the intersection of wearable technology, AI, and epilepsy care. While the company is still in a private, pre-revenue stage, its focus on a high-mortality complication like SUDEP gives it a compelling value proposition. The platform's dual monitoring capability could drive adoption by neurologists and patients seeking proactive risk management. Key challenges include regulatory clearance, clinical validation, and market adoption against established competitors. However, if successful, Neurava could become a standard of care for high-risk epilepsy patients, potentially saving lives and reducing healthcare costs associated with emergency visits and hospitalizations from uncontrolled seizures.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) Submission or Clearance for Wearable Seizure and SUDEP Monitor50% success
• Q3 2026Publication of Clinical Study Results Demonstrating Accuracy of SUDEP Biomarker Detection60% success
• Q1 2027Strategic Partnership or Distribution Agreement with Epilepsy Center Network or Pharma40% success